Formulary guidance and transparency from P&T to point of care


Reality Check on Parkinson's Disease

Market access for Parkinson's disease treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 33% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In May 2020, the FDA approved Sunovion Pharmaceuticals Inc.'s Kynmobi (apomorphine) for the acute, intermittent treatment of "off" episodes in people with Parkinson's disease
  • Key Findings: The Parkinson's market is continually growing, with many drugs in the pipeline. Contracting may occur with multiple monoamine oxidase-B inhibitors available

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.